A Review of Salmeterol-Fluticasone Propionate in Combination: Its Use in the Treatment of Chronic Obstructive Pulmonary Disease

Ohbayashi, Hiroyuki
January 2011
Clinical Medicine Reviews in Therapeutics;2011, Vol. 3, p181
Academic Journal
Tiotropium bromide (TIO), a long-acting anticholinergic bronchodilator, is now used world-wide for the treatment of Chronic Obstructive Pulmonary Disease (COPD). However, the GOLD guidelines recommend another, or additional medication for symptomatic patients with GOLD stage III or IV disease, forced expiratory volume in 1 second (FEV1) less than 50% of the predicted value, and repeated exacerbations. Several lines of evidence such as the TRISTAN study have shown the synergistic effects of a salmeterol- fluticasone propionate combination (SFC), with significant improvements of pulmonary function, health status, exacerbation rates, and quality of life in patients with COPD, compared with using individual components of SFC. But they didn't obtain any improvement in the data for mortality, which is our major clinical concern. The TORCH study is a major study which investigated all-cause mortality rates, but it showed no significant difference of mortality among SFC, individual drugs and placebo groups. The INSPIRE study showed significant improvement of mortality in the SFC treatment group, compared with the TIO. However, the higher incidence of pneumonia in the SFC group remains a subject of debate. Some studies showed that SFC therapy has lower medical costs with good patient compliance, which may become a reason for choosing the therapy. The new 2010 NICE GOLD Guideline recommends the "triple" therapy with SFC and TIO, when the FEV1% predicted is less than 50% in the presence of persistent exacerbations or breathlessness. The advantages of "triple" therapy may outweigh the disadvantages of each medication. This review focuses upon the therapeutic potential of SFC for the treatment of COPD.


Related Articles

  • Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD. Singh, Dave; Nicolini, Gabriele; Bindi, Eddi; Corradi, Massimo; Guastalla, Daniele; Kampschulte, Jorg; Pierzchała, Władysław; Sayiner, Abdullah; Szilasi, Mária; Terzano, Claudio; Vestbo, Jørgen // BMC Pulmonary Medicine;2014, Vol. 14 Issue 1, p1 

    Background: The study evaluated the efficacy of beclomethasone dipropionate/formoterol fumarate (BDP/FF) extrafine combination versus fluticasone propionate/salmeterol (FP/S) combination in COPD patients. Methods: The trial was a 12-week multicentre, randomised, double-blind, double dummy study;...

  • Inhaled Corticosteroids and Pneumonia in Chronic Obstructive Pulmonary Disease. de Molina, Rosa Malo; Restrepo, Marcos I.; Mortensen, Eric M.; Izquierdo, Jose L.; Anzueto, Antonio // Current Respiratory Medicine Reviews;2010, Vol. 6 Issue 3, p162 

    Inhaled corticosteroids (ICS) have been recommended for use in patients with chronic obstructive pulmonary disease (COPD) in order to decrease exacerbation rates and improve health related quality of life parameters. Nevertheless, recent studies have reported an increased risk of pneumonia...

  • Number needed to treat in COPD: exacerbations versus pneumonias. Keene, Oliver N.; Anzueto, Antonio; Ferguson, Gary T.; Calverley, Peter M. A.; Suissa, Samy // Thorax;Sep2013, Vol. 68 Issue 9, p882 

    A letter to the editor is presented in response to the article "Number Needed to Treat in COPD: Exacerbations Versus Pneumonias" by S. Suissa and colleagues in the 2013 issue.

  • Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease. Chatterjee, Arjun; Shah, Manan; D'Souza, Anna O.; Bechtel, Benno; Crater, Glenn; Dalal, Anand A. // Respiratory Research;Feb2012, Vol. 13 Issue 2, p1 

    Background: This retrospective cohort study compared the risks of exacerbations and COPD-related healthcare costs between patients with chronic obstructive pulmonary disease (COPD) initiating tiotropium (TIO) alone and patients initiating triple therapy with fluticasone-salmeterol combination...

  • Out of breath. Snyder, Karyn // Drug Topics;6/26/95, Vol. 139 Issue 12, p44 

    Reports that retail pharmacists and home-health care providers are having difficulty in obtaining Atrovent Inhalation Solution or ipratropium bromide, an anticholinergic bronchodilator in nebulizer form manufactured by Boehringer Ingelheim. Use of the bronchodilator for treatment of chronic...

  • Review: ipratropium is not more effective than β2 agonists for acute exacerbations of chronic obstructive pulmonary disease. McCrory, D. C.; Brown, C. D. // Evidence Based Medicine;May2003, p74 

    The article reviews the study "Anti-Cholinergic Bronchodilators Versus Beta2-Sympathomimetic Agents for Acute Exacerbations of Chronic Obstructive Pulmonary Disease" by D. C. McCrory and colleague. It compares the efficacy of anticholinergic agents against placebo or beta blocker agonists in...

  • Tiotropium for COPD -- The New Standard? Elliott, William T. // Primary Care Reports;May2011 Pharmacology Watch, p1 

    The article presents the results of a study on the anticholinergic drug tiotropium which shows that it is more effective in preventing exacerbation in patients with chronic obstructive pulmonary disease (COPD).

  • Management of COPD and asthma in the 21st century. Kalla, I. S. // CME: Continuing Medical Education;Sep2013, Vol. 31 Issue 9, p331 

    The article focuses on developments chronic obstructive pulmonary disease (COPD) and asthma treatment. In 2012, the Global Initiative Chronic Obstructive Lung Disease recommended exacerbation history as a new algorithm for COPD. New bronchodilator drugs are being developed to control COPD...

  • Managing severe COPD with frequent exacerbations. Booker, Rachel // Practice Nurse;2/26/2010, Vol. 39 Issue 4, p13 

    The article focuses on the management of patients with chronic obstructive pulmonary disease (COPD) who have frequent exacerbations and severe disease. An overview of the disease is provided including the impact of an acute exacerbation of COPD (AECOPD). Management of AECOPD is presented in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics